390 related articles for article (PubMed ID: 22911624)
1. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.
Honda A; Ikegami T; Nakamuta M; Miyazaki T; Iwamoto J; Hirayama T; Saito Y; Takikawa H; Imawari M; Matsuzaki Y
Hepatology; 2013 May; 57(5):1931-41. PubMed ID: 22911624
[TBL] [Abstract][Full Text] [Related]
2. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
Hazzan R; Tur-Kaspa R
J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358
[TBL] [Abstract][Full Text] [Related]
3. Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.
Reig A; Sesé P; Parés A
Am J Gastroenterol; 2018 Jan; 113(1):49-55. PubMed ID: 29016567
[TBL] [Abstract][Full Text] [Related]
4. Bezafibrate treatment: a new medical approach for PBC patients?
Kanda T; Yokosuka O; Imazeki F; Saisho H
J Gastroenterol; 2003; 38(6):573-8. PubMed ID: 12825134
[TBL] [Abstract][Full Text] [Related]
5. Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid.
Takeuchi Y; Ikeda F; Fujioka S; Takaki T; Osawa T; Yasunaka T; Miyake Y; Takaki A; Iwasaki Y; Kobashi H; Yamamoto K; Itoshima T
J Gastroenterol Hepatol; 2011 Sep; 26(9):1395-401. PubMed ID: 21443659
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis.
Dohmen K; Tanaka H; Haruno M
Fukuoka Igaku Zasshi; 2013 Oct; 104(10):350-61. PubMed ID: 24511666
[TBL] [Abstract][Full Text] [Related]
7. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA.
Tanaka A; Hirohara J; Nakanuma Y; Tsubouchi H; Takikawa H
J Gastroenterol; 2015 Jun; 50(6):675-82. PubMed ID: 25239675
[TBL] [Abstract][Full Text] [Related]
8. Primary biliary cirrhosis and bile acids.
Corpechot C
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
[TBL] [Abstract][Full Text] [Related]
9. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid.
Lens S; Leoz M; Nazal L; Bruguera M; Parés A
Liver Int; 2014 Feb; 34(2):197-203. PubMed ID: 23998489
[TBL] [Abstract][Full Text] [Related]
10. Bezafibrate for primary biliary cirrhosis.
Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2012 Jan; 1():CD009145. PubMed ID: 22259000
[TBL] [Abstract][Full Text] [Related]
11. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M
J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185
[TBL] [Abstract][Full Text] [Related]
12. Bezafibrate therapy in primary biliary cholangitis refractory to ursodeoxycholic acid: a longitudinal study of paired liver biopsies at 5 years of follow up.
Sorda JA; González Ballerga E; Barreyro FJ; Avagnina A; Carballo P; Paes de Lima A; Daruich J
Aliment Pharmacol Ther; 2021 Nov; 54(9):1202-1212. PubMed ID: 34587309
[TBL] [Abstract][Full Text] [Related]
13. Additional fibrate treatment in UDCA-refractory PBC patients.
Chung SW; Lee JH; Kim MA; Leem G; Kim SW; Chang Y; Lee HY; Yoon JS; Park JY; Lee YB; Cho EJ; Yu SJ; Kim YJ; Yoon JH
Liver Int; 2019 Sep; 39(9):1776-1785. PubMed ID: 31162879
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis].
Avezov SA; Mansurov FKh
Klin Med (Mosk); 2004; 82(3):55-8. PubMed ID: 15114777
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis].
Avezov SA; Mansurova FKh
Klin Med (Mosk); 2004; 82(2):46-9. PubMed ID: 15106512
[TBL] [Abstract][Full Text] [Related]
16. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia.
Hosonuma K; Sato K; Yamazaki Y; Yanagisawa M; Hashizume H; Horiguchi N; Kakizaki S; Kusano M; Yamada M
Am J Gastroenterol; 2015 Mar; 110(3):423-31. PubMed ID: 25732417
[TBL] [Abstract][Full Text] [Related]
17. Fibrates as adjuvant therapy for chronic cholestatic liver disease: its time has come.
Ghonem NS; Boyer JL
Hepatology; 2013 May; 57(5):1691-3. PubMed ID: 23174993
[No Abstract] [Full Text] [Related]
18. Novel Therapies on Primary Biliary Cirrhosis.
Czul F; Levy C
Clin Liver Dis; 2016 Feb; 20(1):113-30. PubMed ID: 26593294
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid.
Stojakovic T; Putz-Bankuti C; Fauler G; Scharnagl H; Wagner M; Stadlbauer V; Gurakuqi G; Stauber RE; März W; Trauner M
Hepatology; 2007 Sep; 46(3):776-84. PubMed ID: 17668874
[TBL] [Abstract][Full Text] [Related]
20. A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis.
Yagi M; Matsumoto K; Komori A; Abe M; Hashimoto N; Inao M; Namisaki T; Kawata K; Ninomiya M; Fujii H; Takahashi A; Kang JH; Takamura M; Arakawa M; Joshita S; Sato K; Itakura J; Nomura T; Kakisaka K; Kaneko A; Tamura Y; Miura R; Aiso M; Arizumi T; Asaoka Y; Kikuchi K; Takikawa Y; Masaki T; Umemura T; Honda A; Ohira H; Kawada N; Yoshiji H; Mochida S; Takikawa H; Tanaka A;
Liver Int; 2020 Aug; 40(8):1926-1933. PubMed ID: 32438508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
